Cellectis SA ALCLS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
-
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
-
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
-
Cellectis Provides Financial Results for the Second Quarter 2024
-
Cellectis Gets Orphan Designation for Drug Used in Cancer Treatment
-
FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
-
Cellectis: FDA Gives Orphan Drug, Rare Pediatric Status to Leukemia Treatment
-
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 11.47
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 216
- Website
- https://www.cellectis.com
Comparables
Valuation
|
Metric
|
ALCLS
|
NANO
|
IPH
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.41 | — | 5.65 |
Price/Sales | 11.47 | 5.54 | 6.53 |
Price/Cash Flow | — | — | — |
Price/Earnings
ALCLS
NANO
IPH
Financial Strength
|
Metric
|
ALCLS
|
NANO
|
IPH
|
|---|---|---|---|
Quick Ratio | 1.87 | 1.38 | 2.76 |
Current Ratio | 1.92 | 1.42 | 2.92 |
Interest Coverage | −15.16 | −3.42 | −20.73 |
Quick Ratio
ALCLS
NANO
IPH
Profitability
|
Metric
|
ALCLS
|
NANO
|
IPH
|
|---|---|---|---|
Return on Assets (Normalized) | −34.94% | −41.57% | −17.56% |
Return on Equity (Normalized) | −107.90% | — | −67.77% |
Return on Invested Capital (Normalized) | −57.16% | −103.38% | −39.20% |
Return on Assets
ALCLS
NANO
IPH
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Bscfkpndf | Mrs | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Hzyxstvpc | Zmcrbt | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Hvmcmgld | Xpnhhd | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Txrtkgxl | Hzwgsf | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Flvjdwmy | Spr | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Clszdtnw | Tbfm | $28.1 Bil | |||
| Moderna Inc
MRNA
| Ygflkhk | Wggs | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Mjwykwxp | Tnqh | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Cmddsjhr | Mqncr | $13.4 Bil | |||
| Incyte Corp
INCY
| Wqpyhzl | Zrrkt | $12.7 Bil |
United States